Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical CBRN Defense Consortium

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published

March 10, 2022

Issuing agencies

Justice DepartmentAntitrust Division

Full Text

<html>
<head>
<title>Federal Register, Volume 87 Issue 47 (Thursday, March 10, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 47 (Thursday, March 10, 2022)]
[Notices]
[Pages 13756-13757]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-05095]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Medical CBRN Defense Consortium

    Notice is hereby given that, on January 10, 2022, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Medical CBRN Defense 
Consortium (``MCDC'') has filed written notifications simultaneously 
with the Attorney General and the Federal Trade Commission disclosing 
changes in its membership. The notifications were filed for the purpose 
of extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances. 
Specifically, Centivax, Inc., San Francisco, CA; EverGlade 
Pharmaceuticals, Washington, DC; Global Pandemic Prevention and 
Biodefense Center, Arlington, VA; Tutela Pharmaceuticals, Inc., Vernon 
Hills, IL and Vala Sciences, Inc., San Diego, CA have been added as 
parties to this venture.
    Also, Fraunhofer USA Center for Molecular Biotechnology, Newark, 
DE; FUJIFILM Pharmaceuticals USA, Inc., Boston, MA; Full Effect 
Biotech, Inc., Kansas City, KS; GattaCo, Inc., Murrieta, CA; Hawaii 
Biotech, Inc., Honolulu, HI; Indiana Biosciences Research Institute, 
Indianapolis, IN; Integrity Bio, Inc., Camarillo, CA; NYU School of 
Medicine, New York, NY; Rutgers, The State University of New Jersey, 
New Brunswick, NJ; SitScape, Inc., Vienna, VA and The Regents of the 
University of Colorado, Boulder, CO have withdrawn as parties to this 
venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and MCDC intends to file additional 
written notifications disclosing all changes in membership.
    On November 13, 2015, MCDC filed its original notification pursuant 
to Section 6(a) of the Act. The Department of Justice published a 
notice in the

[[Page 13757]]

Federal Register pursuant to Section 6(b) of the Act on January 6, 2016 
(81 FR 513).
    The last notification was filed with the Department on October 1, 
2021. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act on November 24, 2021 (86 FR 67082).

Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2022-05095 Filed 3-9-22; 8:45 am]
BILLING CODE P


</pre></body>
</html>

View on FederalRegister.gov →Plain-text source

Indexed from Federal Register on March 10, 2022.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.